Insulin icodec

Phase 3

Novo Nordisk

Insulin icodec is one of 58 therapeutic programs targeting Diabetes Mellitus, Type 1. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetes Mellitus, Type 1Active, not recruiting

Type 2 DiabetesNot yet recruiting

Diabetes Mellitus, Type 2Recruiting

Diabetes Mellitus, Type 1Phase 3

Active, not recruiting

Type 2 DiabetesPhase 3

Not yet recruiting

Diabetes Mellitus, Type 2Phase 3

Recruiting

Competition

Competitive Landscape

171 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Insulin icodec

Novo Nordisk

Phase 3

1 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Cysteine Hydrochloride

Novartis

Preclinical

1 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

2 10

Routine Treatment

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Active, not recruiting

Diabetes Mellitus, Type 1

NCT07160816

Phase 3Active, not recruiting

Diabetes Mellitus, Type 1

NCT07076199

Q1 2028

Recruiting

Diabetes Mellitus, Type 1

NCT06807190

ApprovedNot yet recruiting

Type 2 Diabetes

NCT07747402

ApprovedRecruiting

Diabetes Mellitus, Type 2

NCT07112339

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 24 trials

A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Switch From Daily Basal Insulin to Insulin Icodec in People Living With Type 2 Diabetes in Italy

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT07632404·214 enrolled

Enrolling by invitation· Novo Nordisk logo

Novo Nordisk··NCT07658417·216 enrolled

Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT04760626·1,085 enrolled

Show 1 more trial

EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice

Recruiting· Novo Nordisk logo

Novo Nordisk·Approved·NCT07112339·586 enrolled

Diabetes Mellitus, Type 13 trials

A Real-world, Multi-centre, Prospective, Non-interventional, Single-arm Study Investigating Glycaemic Control, Treatment Satisfaction and Adherence Associated With the Use of Insulin Icodec in People Living With Type 1 Diabetes

Active, not recruiting· Novo Nordisk logo

Novo Nordisk··NCT07160816·245 enrolled

A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07076199·877 enrolled

A Multi-centre, Prospective, Open Label, Non-interventional, Single-armed, 52 Weeks Post-marketing Study to Investigate Safety and Clinical Parameters of Awiqli Once Weekly in Patients With Diabetes Mellitus Under Real-world Clinical Practice Setting in Japan

Recruiting· Novo Nordisk logo

Novo Nordisk··NCT06807190·630 enrolled

Diabetes, Type 21 trial

A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06340854·412 enrolled

Type 2 Diabetes1 trial

Effects of Different Insulin Icodec Initiation Strategies and a Day-4 Supplemental Dosing Decision on Early Fasting Blood Glucose Target Attainment in Type 2 Diabetes: A Multicenter, Randomized, Open-Label, 3x2 Factorial Trial

Not yet recruiting·XXi'an International Medical Center Hospital·Approved·NCT07747402·462 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Insulin icodec. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Insulin icodec. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Novo Nordisk

Insulin icodec

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Diabetes Mellitus, Type 24 trials

Diabetes Mellitus, Type 13 trials

Diabetes, Type 21 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News